2020 CEPOP Annual All-Participants Strategy Session

Monday, January 27, 2020

3:00pm - 4:30pm

Washington, DC



WiFi: FaegreBD-Guest **Password:** ClientsFirst





Welcome, Introduction and Meeting Goals

Focus Topic Presentation

• CDC: Understanding the Data – The Scope and Evolution of the Opioid Epidemic

2019 In Review: CEPOP Successes and Deliverables

Developing CEPOP's 2020 Agenda

- Strategic Priorities
- Building Consensus
- Raising Visiblity and Negagement

Moving Forward: Setting an Agenda into Action



Focus Topic Discussions:

Understanding the Data — The Scope and Evolution of the Opioid Epidemic

Michelle Putnam

Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control

Centers for Disease Control and Prevention

National Center for Injury Prevention and Control




The Opioid Overdose Epidemic


CEPOP Annual Strategy Session

Michelle Putnam, MPH Lead, Policy and Partnership Division of Overdose Prevention

3 Waves of the Rise in Opioid Overdose Deaths



CDC's Approach: Opioid Overdose Prevention





Division of Overdose Prevention GOALS


1 Reduce opioid overdose now

2 Identify and address emerging drug trends and associated public health outcomes

Prevent drug use initiation or drug misuse among youth and young adults

Overdose Data to Action (OD2A)

- Competitive award process
- Integrates previous funding into one announcement
- \$300M per year for 3 years (starting in 2019)
- States, cities, counties, and territories
- Seamless integration of data and prevention



Surveillance

Required Strategies

- Morbidity
 - Reporting every 2 weeks, monthly, or quarterly
- Mortality
 - Lag of 6-11 or 8-13 months
- Innovative project(s)

Optional Strategies

- Additional quarterly reporting of hospital billing data
- Suspected opioid overdose death collection (<1 month)

Prevention

Required Strategies

- Improving PDMP
- State/local integration
- Linkages to care
- Providers and health systems support

Optional Strategies

- Public safety partnerships
- Empowering individuals
- Prevention innovation project
- Peer-to-peer learning coordination

West Virginia Ohio Pennsylvania District of Columbia Kentucky Delaware New Hampshire Maryland Maine Massachusetts Rhode Island Connecticut New Jersey Indiana Michigan Tennessee Florida New Mexico Louisiana North Carolina Missouri Vermont Utah Arizona Illinois Nevada Wisconsin South Carolina Alaska Oklahoma New York Alabama Virginia Colorado Arkansas Washington Georgia Idaho Hawaii Minnesota **Age-Adjusted** Oregon Wyoming **Drug Overdose** Mississippi **Death Rate** Kansas Montana California lowa 2013 2017 North Dakota South Dakota Nebraska Deaths per 100,000 population

Drug overdose deaths increasing across America from 2013 to 2017

- The number of opioid deaths in the United States almost doubled from 25,052 to 47,600
- For context, there were 8,050 opioid deaths in 1999
- A total of 35 states had a statistically significant increase in their drug overdose death rate
- WV had the highest absolute rate at both time points
- DC, WV, OH, PA, NH, MD and ME had the largest absolute rate increase each over 20 deaths per 100,000 people
- The death rate over doubled in 10 areas ND, DC, ME, MD, NH, PA, OH, NJ, FL, MA

Source: Scholl, Seth, Kariisa, Wilson, Baldwin (2019); NCHS Data Brief 329 (2019)

Based on data available for analysis on: 1/5/2020 Select Jurisdiction Select specific drugs or drug classes United States (Multiple values) Figure 2. 12 Month-ending Provisional Number of Drug Overdose Deaths by Drug or Drug Class: United States 50,000 40,000 Number of Deaths 30,000 20,000 10,000 0 Jan 2015 Jul 2015 Jan 2016 Jul 2016 Jan 2017 Jul 2017 Jan 2018 Jul 2018 Jan 2019 12 Month-ending Period - Reported Value Legend for Drug or Drug Class Opioids (T40.0-T40.4,T40.6) Methadone (T40.3) O Predicted Value Heroin (T40.1) Synthetic opioids, excl. methadone (T40.4) Natural & semi-synthetic opioids (T40.2) Cocaine (T40.5) Psychostimulants with abuse potential (T43.6)



Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential in the US

Opioid Deaths Nested in a Broadening Drug Overdose Epidemic. . .

Death Rates Percent Increase from 2010 - 2017

Cocaine Overall 231

Cocaine without ANY Opioids 83

Psychostimulant Overall 433

Psychostimulant without ANY Opioids 300

Deaths Percent of Deaths 2017

Cocaine with ANY Opioid 72.7

Psychostimulant with ANY Opioid 50.4

Number of opioid overdose deaths by opioid type in 25 states from January to June 2018

Opioid	deaths	with	information	on involved
	opioids	, Jan-	-Jun 2018, no	o. (%)

Characteristic	opioids, Jan–Jun 2018, no. (%)		
Total opioid overdose deaths	13,415 (100)		
Opioid drug class or drug involved in opioid deaths			
Any prescription opioid	3,853 (28.7)		
Any illicit opioid	11,124 (82.9)		
Any suspected IMF	9,105 (67.9)		
Any suspected heroin	5,281 (39.4)		
Any fentanyl analog	2,678 (20.0)		
Any U-series	63 (0.5)		

Common mutually exclusive combinations of opioids involved in opioid deaths

Opioid combinations co-involving IMF

IMF with no other illicit opioids	4,320 (32.2)	
IMF with heroin	2,566 (19.1)	
IMF with fentanyl analogs	1,172 (8.7)	
IMF with heroin and fentanyl analogs	1,008 (7.5)	
Illicit opioid combinations not co-involving IMF		
Heroin with no other illicit opioid	1,534 (11.4)	
Fentanyl analogs with no other illicit opioid	312 (2.3)	
Prescription opioid with no illicit opioid	2,291 (17.1)	
All other combinations of opioids	212 (1.6)	

Note: IMF is illicitly manufactured fentanyl. Refer to source for other footnotes

Polysubstance epidemic driven by illicitly-manufactured fentanyl




Morbidity and Mortality Weekly Report

August 30, 2019

Weekly / Vol. 68 / No. 34

Source: Gladden, O'Donnell, Mattson, Seth (2019)
Data = State Unintentional Drug Overdose Reporting System (SUDORS)

Patterns in Amount of Opioids Prescribed and Mean Duration per Prescription, United States, 2006-2017





2x


The number of prescriptions for naloxone doubled from 2017 to 2018.

1 in 70

Only 1 naloxone prescription is dispensed for every 70 high-dose opioid prescriptions.

3x

Rural counties are nearly 3 times more likely to be ranked low dispensing than metropolitan counties.





www.cdc.gov/ drugoverdose



CDC Publications

Featured Article



An Examination of Concurrent Opioid and Benzodiazepine Prescribing in Nine States, 2015 [4]

This report analyzes concurrent prescribing of opioid and benzodiazepine in nine states using the 2015 Prescription Behavior Surveillance System. More than half of patients with concurrent opioids and benzodiazepines received prescriptions from two or more different providers. Despite the known risks of taking these

medications in combination, concurrent prescribing of opioids and benzodiazepines is common. These findings highlight the need for public health action, such as evidence-based guidelines and prescription drug monitoring programs to reduce concurrent prescribing.

Read More »



Journal Articles



MMWR Articles



CDC Vital Signs



Guides and Meeting Reports




Related Publications



PBSS Data Briefs





For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov

Web: www.cdc.gov

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



2019 in Review: CEPOP Successes Advocacy Agenda



FY2020 Appropriations Letters Submitted



Implementation of the October 2018 SUPPORT for Patients and Communities Act Drug Packaging and Disposal Medicare Access

to All FDA-Approved MAT Products



Continued focus on fraud, waste and abuse within SUD treatment and recovery and potential preventative measures.

2019 in Review: CEPOP Successes Policy Development

CEPOP's Webinar on Combatting the Opioid Epidemic Through Safe Disposal Strategies

June 2019 Hill Briefing on Safe Opioid Management in the Acute Care Setting

Continued collaboration with state and federal agency partners, policymakers, regulators and others around CEPOP priorities.





Monthly *All-Participants Meetings* with Focus Topic
Speaker presentations.

Public- and private-sector initiatives highlighted.

Expansion of CEPOP membership via focus topics.



Circulation of Weekly Opioid Policy Report (substantial growth of recipients)



National Rx Drug Abuse Summit
Session Participation and Member Reception



Continued expansion of CEPOP participation.

Developing a 2020 Agenda

Identification of organizational priorities and advancing consensus around a 2019 workplan.



CEPOP's Strategic Priorities



Prevention

Safe Disposal & Anti-Diversion


Safe Use

Federal Budget and Appropriations



Framing Prevention: Evidence-Based Community Inverventions

Sue Thau, CADCA



CADCA's Model for Community Change

Sue Thau
Public Policy Consultant
CADCA



Keys to Pushing Back Against the Use and Abuse of Rx Drugs

com·pre·hen·sive

/ kämprə hensiv/

adjective

complete; including all or nearly all elements or aspects of something.
 "a comprehensive list of sources"

 Approach that appropriately mobilizes each of the key sectors and actors who have a role in reducing access to and availability of prescription drugs

Key Sectors

- Coalitions convene and combine talent and resources to address local substance misuse issues:
 - Law enforcement
 - Youth
 - Parents
 - Businesses
 - Media
 - Schools
 - Youth serving organizations

- Faith based community
- Civic and volunteer groups
- Health care professionals
- State, local or tribal agencies
- Other organizations involved in reducing substance misuse

Community Problem Solving




Strategic Prevention Framework

CADCA's Specialized Training (Required of All Year 1 DFCs)

Results in successful completion of 5 products:

- Community Assessment
- Logic Model
- Strategic & Action Plan
- Education Plan
- Sustainability Plan

CADCA's 7 Strategies for Community Change



CASE STUDY: CARTER COUNTY DRUG FREE COALITION

Carter County, Kentucky



cadca.org

DRUG USE PREVENTION



1. Providing Information

- Media Campaigns (Inundated the community)
 - Lock Em' Up
 - Doctor Shopping
 - Forget Everything Your Mother Taught You About Sharing
- Social Norms Media Campaign-Billboards, newspaper ads, radio PSAs, push cards, bulletin inserts, posters, school athletic program ads, movie theater ad/commercial, at local events

2. Building Skills

Provided training in Teens As Teachers in ATOD training

Parent/Guardian/Adult trainings

School Faculty/Staff trainings

Health Professional Training-"Pharmacology, Polypharmacy and Addiction"

Lifeskills Curriculum in 3rd-9th grades

Generation Rx Curriculum 9th Grade and community groups (ex. Boy Scouts and Church Youth Groups)

3. Providing Support

Provided funding for law enforcement to attend NADDI and other drug suppression trainings

Secured funding for drug investigation overtime

Secured funding for one and one-half substance abuse counselors

Provided support for Lifeline Recovery Support Groups

Health Professionals Toolkit

4. Enhancing Access/Reducing Barriers

Prescription Drop Box-started as an event now permanent at Sheriff's Office

Safe Homes Network

5. Changing Consequences (incentives/disincentives)

Increased DUI/Drug Suppression Checks

Drug Free Workplace Initiative throughout the community

6. Change Physical Design

Create a campaign to get people to "lock their meds"

Collaborate with builders and realtors to ensure "Rx Safe Boxes" are installed or available in homes for sale

GIS mapping

Promote signage at key locations (e.g. pharmacies, doctors, dentists or therapists offices)


7. Modify and Change Policies

First Pain Clinic Ordinance for the county passed in Kentucky

Worked to help businesses pass Drug Free Workplace policies-worked with local Chamber of Commerce

Have a drug free policy veteran's must sign to move into the tiny homes built to reintegrate veterans when they come back from deployment and reintegrating them to civilian life

30-day Prescription Drug Use



School test scores have risen so that Carter County Schools were awarded a Distinguished District/District of Distinction and East Carter High School a Distinguished School/School of Distinction and Kentucky HUB School!


College and Career Readiness scores from 23% in 2010 to 87% in 2017; ACT scores from 16.8 in 2007 to 19.3 in 2017; Graduation rates from 83.6% in 2007 to 99.5% in 2017.

Scioto County, Ohio

- Received DFC grant (2012-2018)
- Attended CADCA Institute Academy Training
- Full implementation of the CADCA model

RESULTS


DFC Core Measure Data Past 30-Day Use Over a Five Year Period Grades 6-12 Scioto County, Ohio 2013 (Baseline)-2018 (Current)



Substance Use by Survey Year


■ 2013-2014 ■ 2015-2016 ■ 2017-2018

Opioid Doses Dispensed Per Capita to Ohio Patients by County and Quarter



46% decrease in Rx opioids dispensed per capita (quantity)


Average Daily MED Per Capita to Ohio Patients by County and Quarter





59% decrease in average daily MED per capita (strength)

Newborns Treated Pharmacologically for NAS Scioto County, Ohio 2012-2016




Jackson County, West Virginia

- Received DFC grant (2007-2017)
- Attended CADCA Institute Academy Training
- Full implementation of CADCA Model

RESULTS

Change in 30-Day Prevalence of Use Jackson County High School Students



In Closing

- The comprehensive coalition approach is the best local solution to address any public health threat and is especially critical with the complex opioid and heroin crisis we face as a nation.
- Data shows that **DFC coalitions** are having success in this area and **CADCA's National Coalition Institute** is a factor in making coalitions more effective.



- Development of targeted policy, funding, or educational campaigns.
 - Demography?
 - Geography?
- What do future initiatives look like?
- Who are partners for this?
- How does this tie-in to the evolving substance abuse epidemic?



- Where do we go from CEPOP's National Webinar given its interest and success?
- How does these efforts tie-in to:
 - SUPPORT Act Provisions?
 - FDA's Remove the Risk Campaign?
 - Environmental concerns?
 - Clearinghouse legislation?
- Emphasis around closing the pharmaceutical life cycle.



- How doe we improve access to safer acute and chronic pain therapies?
- Is there a demographicspecific component to this workstream (e.g. pediatrics or older adults)?

Strategic Priority: Federal Budget and Appropriations

Do we continue this core advocacy work? If so, where do we emphasize?

2020 CEPOP Annual Strategy Session 34

Developing a 2020 Agenda: Building Consensus

Are these the right areas of focus? How does CDC's presentation impact our future efforts?



Raising Visibility & External Engagement

2020 Presidential Election – Opportunities and Implications

Events & Convenings (Rx Summit, Briefings, etc.)



Resources (e.g. Website and Policy Report)

Growth in Membership

Developing a 2020 Agenda

Where do we go from here?



Moving Forward: Setting an Agenda into Action

Our Next *CEPOP All-Participants Teleconference:*

Monday, February 24, 2020 3:00pm – 4:00pm

Calendar Appointment Forthcoming



Thank You!

We look forward to continuing our efforts together in combatting the opioid epidemic in 2020 and beyond!

2020 CEPOP Annual Strategy Session 39